Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class
of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti …

RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …

Rat sarcoma (RAS), as a frequently mutated oncogene, has been studied as an attractive
target for treating RAS‐driven cancers for over four decades. However, it is until the recent …

RAS genes are the most frequently mutated oncogenes and play critical roles in the
development and progression of malignancies. The mutation, isoform (KRAS, HRAS, and …

Ras genes are frequently activated in cancer. Attempts to develop drugs that target mutant
Ras proteins have, so far, been unsuccessful. Tumors bearing these mutations, therefore …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …